Bio

BUSINESS

Vor Bio back from brink with autoimmune drug deal rising to $4bn

A month and a half after winding operations and laying off almost all its staff, Vor Bio has emerged from…

Read More »
BUSINESS

Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report

By Exec Edge Research Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones…

Read More »
Back to top button